## **Announcement Summary**

## **Entity name**

CHALLENGER LIMITED

## **Announcement Type**

New announcement

### Date of this announcement

Tuesday October 13, 2020

## The Proposed issue is:

☑ A non pro rata offer of securities under a disclosure document or product disclosure statement (PDS)

Total number of +securities proposed to be issued for a non pro rata offer of securities under a disclosure document or product disclosure statement (PDS)

ASX +Security Code	+Security Description	Maximum Number of +securities to be issued
n/a	Challenger Capital Notes 3 (ASX: CGFPC)	2,500,000

## Closing date for receipt of acceptances

Friday November 13, 2020

## Proposed +issue date

Wednesday November 25, 2020

Refer to next page for full details of the announcement

## Part 1 - Entity and announcement details

### 1.1 Name of +Entity

CHALLENGER LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

## 1.2 Registered Number Type

**Registration Number** 

ABN

85106842371

### 1.3 ASX issuer code

CGF

## 1.4 The announcement is

☑ New announcement

### 1.5 Date of this announcement

Tuesday October 13, 2020

### 1.6 The Proposed issue is:

☑ A non-+pro rata offer of +securities under a +disclosure document or +PDS

## Part 5 - Details of proposed non-pro rata offer under a disclosure document or PDS

#### Part 5A - Conditions

5A.1 - Are any of the following approvals required for the non-+pro rata offer of +securities under a +disclosure document or +PDS?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

Yes

5A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or	** Approval
Other (please specify in	Friday October 2, 2020	actual?	received/condition met?
comment section)			Yes

#### Comments

APRA approval for the new issue of Challenger Capital Notes 3 and Challenger Life Company Notes 3 and resale/redemption of Challenger Capital Notes and Challenger Life Company Notes issued on 9 October 2014.

Part 5B - Offer details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? 

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

Have you received confirmation from Will the entity be seeking quotation ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1? Yes

of the 'new' class of +securities on ASX? Yes



#### Proposed issue of securities

### **ASX +Security Code**

## +Security Description

New class-code to be confirmed

Challenger Capital Notes 3 (ASX: CGFPC)

## +Security Type

Other

Maximum Number of +securities proposed to be issued

2,500,000

Minimum Number of +securities proposed to be offered to each individual +security holder

Maximum Number of +securities proposed to be offered to each individual +security holder

Minimum subscription \$ amount proposed to be offered to each individual security holder

Maximum subscription \$ amount proposed to be offered to each individual security holder

## Purpose of the issue

The proceeds of the issue will be used to fund the regulatory capital requirements of Challenger Life Company Limited and to refinance the Challenger Capital Notes issued on 9 October 2014.

# In what currency will the offer be made?

What is the offer price per +security?

AUD - Australian Dollar

AUD 100.00000

Offer price details for institutional security holders

Could offer price per +security be determined by bookbuild? 
⊗ No

Oversubscription & Scale back details

Are +security holders allowed to oversubscribe? 

✓ Yes

## Provide the oversubscription details

Challenger may issue more or less than 2,500,000 Challenger Capital Notes 3. Please refer to section 7.6.2 of the Prospectus lodged with the ASX on 13 October 2020 for details of Challenger's allocation policy in respect of the Challenger Capital Notes 3.

## May a scale back be applied to this event?

✓ Yes

#### Provide the scale back details

Challenger's current intention is to give preference to Applicants under the Reinvestment Offer over Applicants under the Securityholder Offer. Refer to section 7.6.2 of the Prospectus for further details.

# Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

## Please provide any further information relating to the principal terms of the +securities

Please refer to the Prospectus for further details about the terms of Challenger Capital Notes 3. The terms of the Challenger Capital Notes 3 are set out in full in Appendix A to the Prospectus. The terms are also summarised in section 2 of the Prospectus.

#### Part 5C - Timetable

#### 5C.1 Lodgement date of +disclosure document or +PDS with ASIC

Tuesday October 13, 2020

# 5C.2 Date when +disclosure document or +PDS and acceptance forms will be made available to investors

Wednesday October 21, 2020

#### 5C.3 Offer open date

Wednesday October 21, 2020

## 5C.4 Closing date for receipt of acceptances

Friday November 13, 2020

### 5C.6 Proposed +issue date

Wednesday November 25, 2020

### Part 5D - Listing Rule requirements

5D.1 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? 
⊗ Yes

## 5D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

Thursday October 29, 2020

### Part 5E - Fees and expenses

# 5E.1 Will there be a lead manager or broker to the proposed offer? ✓ Yes

#### 5E.1a Who is the lead manager/broker?

The Joint Lead Managers are National Australia Bank Limited; UBS AG, Australia Branch and Westpac Institutional Bank.



### 5E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Please refer to Section 9.1.4 of the Prospectus for details of the fees payable to the Joint Lead Managers.

## 5E.2 Is the proposed offer to be underwritten?

☑ No

# 5E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

Yes

## 5E.3a Will the handling fee or commission be Dollar based or Percentage based?

☑ Percentage based (%)

# 5E.3b Amount of any handling fee or commission payable to brokers who lodge acceptances on behalf of investors

1.500000 %

#### 5E.3c Please provide any other relevant information about the handling fee or commission method

Challenger will be responsible for paying the Joint Lead Managers fees paid proportionately to each Joint Lead Manager on the basis of their Challenger Capital Notes 3 allocation.

The Joint Lead Managers on behalf of Challenger are responsible for paying all selling fees and other commissions payable to the Syndicate Brokers.

## 5E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

Please refer to section 9.2 of the Prospectus for details in relation to the expenses of the Offer.

Part 5F - Further Information

# 5F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? ⊗ No

# 5F.2 The entity's allocation policy for the offer, including whether or not acceptances from existing +security holders will be given priority

Please refer to section 7.6 of the Prospectus for details in relation to the allocation policy.

### 5F.3 URL on the entity's website where investors can download the +disclosure document or +PDS

www.challengercapitalnotes.com.au

#### 5F.4 Any other information the entity wishes to provide about the proposed offer

Investors should read the Prospectus in full before deciding to invest in Challenger Capital Notes 3 and consider the risks that could affect the performance of Challenger Capital Notes 3.